Macroaxis does not monitor all media channels or aggregates social signals for Theravance. But even though we do not provide professional-grade financial sentiment analysis on Theravance Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Theravance. Also please take a look at World Market Map.
Thorold NewsBuckeye Partners L.p. - BPL - Stock Price Today - Zacks Zacks Get full coverage
StockNewsTimesAs Theravance Biopharma Share Value Rose, Baupost Group Has Increased by 1.20 Million Its Holding ... Wolcott DailyEPS for Theravance Biopharma, Inc. Expected At -1.15 8 Analysts Covering Waste Management, Inc. NormanObserver.com Get full coverage
The Ledger Gazette0.52 EPS Expected for Innoviva Inc This Quarter StockNewsTimes Get full coverage
BZ WeeklyEPS for Theravance Biopharma, Inc. Expected At -1.15 ReuropeTheravance Biopharma, Inc. Analysts See -1.15 EPS KL Daily Get full coverage
This outcome is the result of a proxy contest Sarissa Capital waged in connection with Innoviva 2017 annual stockholder meeting and Sarissa Capital necessary subsequent litigation against Innoviva. In December 2017, Sarissa Capital prevailed in its ...
The shares of Innoviva, Inc. have increased by more than 8.74 percent this year alone. The shares recently went up by 11.81 percent or 1.63 and now trades at 15.43. Innoviva, Inc. recently sold by insider Aguiar Michael W - Post Analyst Innoviva Lifted to Hold at Zacks Investment Research - Dispatch Tribunal
Innoviva, Inc. closed at 15.43 after seeing 2749212 shares trade hands during the most recent session. Innoviva Inc Receives 12.50 Consensus Target Price from Analysts - registrarjournal.com Dimensional Fund Advisors LP Increases Stake in Innoviva Inc - TrueBlueTribune
StockNewsTimes Get full coverage
FLBC News Get full coverage
BRISBANE, Calif. Innoviva Inc. on Thursday reported fourth-quarter earnings of 58.4 million. The Brisbane, California-based company said it had profit of 45 cents per share.
Innoviva Inc shares traded 0.36 percent up during most recent session to reach at the closing price of 13.99. The stock exchanged hands 1.71 Million shares versus average trading capacity of 827.28 Million shares, yielding a market cap of 1.56 ... 0.45 EPS Expected for Innoviva, Inc. - BZ Weekly Zacks Investment Research Downgrades Innoviva to Sell - StockNewsTimes
The Price to Book ratio for Innoviva, Inc. NasdaqGSINVA is -6.971364. The Price to book ratio is the current share price of a company divided by the book value per share.
Innoviva is set to issue its quarterly earnings data after the market closes on Wednesday, February 7th. Analysts expect the company to announce earnings of 0.38 per share for the quarter. Innoviva, Inc. Investor Update and Valuation Review - DARC News Innoviva Stock Rating Lowered by Zacks Investment Research - Week Herald
Innoviva logo Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals.
Dimensional Fund Advisors LP grew its stake in Innoviva Inc by 22.4 percent in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. Innoviva Downgraded by Zacks Investment Research to Sell - The Lincolnian Online